BioArctic

BioArctic Profit per Employee

The Profit per Employee of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 23.77 M SEK. In the previous year, Profit per Employee was -4.12 M SEK — a change of -677.33% (higher).

Profit per Employee

23.77 MSEK

YoY

-677.33%

Last updated:

Profit per Employee of BioArctic is 2025 23.77 M SEK. Profit per Employee of BioArctic was 2024 -4.12 M SEK. It decreases by -677.33% higher compared to the previous year.

The BioArctic Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
8.87 M SEK
Jan 1, 2019
2.06 M SEK
Jan 1, 2020
-1.59 M SEK
Jan 1, 2021
-2.79 M SEK
Jan 1, 2022
-259,953.49 SEK
Jan 1, 2023
5.33 M SEK
Jan 1, 2024
-4.12 M SEK
Jan 1, 2025
23.77 M SEK
The BioArctic Profit per Employee history
YEARProfit per EmployeeYoY
23.77 MSEK-677.33%
-4.12 MSEK-177.24%
5.33 MSEK-2,150.89%
-259,953.49SEK-90.67%
-2.79 MSEK+74.83%
-1.59 MSEK-177.45%
2.06 MSEK-76.82%
8.87 MSEK+2,417.66%
352,488.37SEK-73.68%
1.34 MSEK+1,452.02%
86,279.07SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Profit per Employee of BioArctic is 23.77 M SEK in 2025.

Profit per Employee of BioArctic changed from -4.12 M SEK to 23.77 M SEK, representing a -677.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee BioArctic since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — BioArctic

All Key Metrics — BioArctic